clinical trial · NCT03367403
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
Eli Lilly and Company·phase2·completed·n = 272
Alzheimer DiseaseDonanemabPlaceboLY3202626
brief summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
started
Dec 18, 2017
primary completion
Dec 4, 2020
completion
Sep 21, 2021
last updated
Mar 19, 2026
official title
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol